mna-279 and Lupus-Erythematosus--Systemic

Topics: Acrylamide; Acrylamides; Alkynes; Animals; Antibody Formation; Autoantibodies; Autoimmune Diseases; Caproates; Crosses, Genetic; Female; Glomerulonephritis; Graft vs Host Disease; Immunoglobulin E; Immunoglobulin G; Immunosuppressive Agents; Isoxazoles; Lupus Erythematosus, Systemic; Lymphocyte Transfusion; Mice; Mice, Inbred C57BL; Mice, Inbred DBA; Mice, Mutant Strains; Nitriles; Spleen; Transplantation, Homologous

Topics: Aging; Alkynes; Animals; Autoimmune Diseases; Female; Immunosuppressive Agents; Isoxazoles; Kinetics; Lupus Erythematosus, Systemic; Lymph Nodes; Mice; Mice, Inbred DBA; Nitriles; Spleen; Splenomegaly

The use of inbred mouse strains of defined genetic background has allowed for the development of systems capable of reproducibly generating either an acute or chronic graft-versus-host disease (GvHD). The malononitrilamides MNA 279 and MNA 715, analogues of the main metabolite of leflunomide, have been shown to directly inhibit T-cell proliferation and B-cell functions. Therefore, they have been studied in a local GvH reaction in the popliteal lymph node (PLN) assay in LBN rats, on the development of an acute and lethal GvHD in B6C3F1 mice and on a chronic autoimmune GvHD in BDF1 hybrid mice. In the PLN assay an oral administration of various concentrations (7.5 to 50 mg/kg) of both MNAs inhibited the localized GvH reaction dose-dependently and suppressed the lymph node hyperplasia. Both MNAs also acted therapeutically in this assay when they were given as late as day 4 or 5 after challenge. In the model of an acute lethal GvHD the treatment of the GvH-B6C3F1 hybrid mice with the MNAs (2.5 to 20 mg/kg/day) shortly after disease induction on days 3 to 12 resulted in a dose-dependently improved survival rate. With 20 mg/kg of drugs, mortality of this life-threatening GvHD was completely prevented and also other parameters like splenomegaly, erythrocyte counts and hematocrit values were strongly suppressed. Treatment of sensitized GvH-BDF1 hybrid mice in the chronic autoimmune-like model with the MNAs (30 mg/kg/day), given on days 3 to 36 by oral gavage, resulted in an improved survival rate, inhibited lymphadenopathy and splenomegaly, reduced the levels of autoantibodies and other immunoglobulins like IgE and IgG1, prevented proteinuria and the development of glomerulonephritis. Both MNA 279 and MNA 715 can inhibit ongoing aberrant immune responses in animals suffering from GvHD.

Topics: Alkynes; Animals; Disease Models, Animal; Graft vs Host Disease; Graft vs Host Reaction; Immunosuppressive Agents; Isoxazoles; Lupus Erythematosus, Systemic; Lymph Nodes; Mice; Mice, Inbred C3H; Mice, Inbred C57BL; Nitriles; Rats; Rats, Inbred BN; Rats, Inbred Lew

Topics: Aging; Alkynes; Animals; Antibody Formation; Crosses, Genetic; Disease Models, Animal; Female; Graft vs Host Disease; Immunoglobulin E; Immunoglobulin G; Immunosuppressive Agents; Isoxazoles; Lupus Erythematosus, Systemic; Mice; Mice, Inbred DBA; Mice, Mutant Strains; Nitriles

Topics: Alkynes; Animals; Graft vs Host Disease; Graft vs Host Reaction; Immunosuppressive Agents; Isoxazoles; Lupus Erythematosus, Systemic; Lymphocyte Transfusion; Mice; Mice, Inbred C57BL; Mice, Inbred DBA; Mice, Inbred Strains; Nitriles; Rats; Rats, Inbred Lew; Rats, Inbred Strains; Spleen; Splenomegaly; Time Factors; Transplantation, Homologous